chimerix
participate
upcoming
investor
conferences
durham
globe
newswire
chimerix
nasdaq
cmrx
biopharmaceutical
company
focused
accelerating
development
medicines
treat
cancer
serious
diseases
today
announced
management
participate
following
investor
conferences
september
wainwright
annual
global
investment
conference
chimerix
present
corporate
overview
monday
september
et
participate
investor
meetings
chimerix
present
corporate
overview
monday
september
et
participate
investor
meetings
cantor
fitzgerald
virtual
healthcare
conference
management
participate
investor
meetings
wednesday
september
live
audio
webcast
wainwright
conference
presentation
available
investor
relations
section
chimerix
website
archived
approximately
days
chimerix
chimerix
biopharmaceutical
company
dedicated
accelerating
advancement
innovative
medicines
make
meaningful
impact
lives
patients
living
cancer
serious
diseases
two
development
programs
dociparstat
sodium
dstat
brincidofovir
bcv
dstat
potential
glycosaminoglycan
compound
derived
porcine
heparin
compared
commercially
available
forms
heparin
may
dosed
higher
levels
without
associated
complications
dstat
studied
phase
trial
assess
safety
efficacy
adults
acute
lung
injury
underlying
phase
trial
protocol
study
dstat
acute
myeloid
leukemia
agreed
us
food
drug
administration
fda
site
activation
expected
early
bcv
antiviral
drug
candidate
development
medical
countermeasure
smallpox
information
please
visit
chimerix
website
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
factors
risks
could
cause
actual
results
differ
materially
indicated
statements
set
forth
company
filings
securities
exchange
commission
statements
represent
company
judgment
date
release
company
disclaims
however
intent
obligation
update
statements
contact
investor
relations
michelle
laspaluto
ir
connor
stern
investor
relations
media
david
schull
russo
partners
